Cardiovascular

Glucagon-like peptide-1 (GLP-1) receptor agonists provide similar reductions in major adverse cardiovascular events, all-cause death, and cardiovascular-related death in patients with overweight and obesity who do not have diabetes and in patients with diabetes.

Researchers discovered a causal relationship between air pollutants and increased cardiovascular disease (CVD) risk, highlighting the need for protective measures to mitigate exposure.

The home-based care model offers a promising strategy for improving quality of care, while also reducing health care spending.

Extreme temperatures and hurricanes are strongly associated with worsening cardiovascular health, a study finds.

The low-calorie sweetener was associated with incident major adverse cardiovascular event risk, according to one study.

This study evaluated whether limited English proficiency modifies the association between cardiovascular risk factors or cardiovascular disease and outcomes in patients hospitalized with COVID-19.

Having a higher magnesium depletion score (MDS) independently predicts increased all-cause and cardiovascular mortality risks in US patients with hypertension (HTN), emphasizing the importance of early HTN prevention and magnesium deficiency management.

This week, the Center on Health Equity and Access covers news related to AI integration, disparities in pediatric hospitalizations, new advancements presented at the 2024 CMS Health Equity Conference, and an expert discussion on the cardiovascular field.

Ronesh Sinha, MD, attributes the rising rates of heart disease to sedentary lifestyles, stress, and health inequities, while advocating for digital health solutions to improve preventive care.

Using a microsimulation approach, this study modeled the potential multiyear health and economic benefits of participating in cardiometabolic virtual-first care programs.

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Cardiovascular disease (CVD) risk was reduced by 1.2% in the intention-to-treat analysis and 5% in the per protocol analysis for adults aged 75 and older.

New research has shown a link between children’s consumption of ultraprocessed foods and their risk of obesity and other cardiometabolic problems.

Risk assessments of drug-related problems for cardiac surgery patients can be conducted by implementing a framework for patient safety.

The findings show exercise-induced hypertension increases myocardial oxygen demand.

These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.

In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.

Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.

Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.

For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.

This expansion applies to the estimated 70 million patients who need either primary or secondary prevention, regardless of statin use.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.

Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.